131 related articles for article (PubMed ID: 30273620)
1. Hypothesis-driven weight-of-evidence analysis for the endocrine disruption potential of benzene.
Mihaich EM; Borgert CJ
Regul Toxicol Pharmacol; 2018 Dec; 100():7-15. PubMed ID: 30273620
[TBL] [Abstract][Full Text] [Related]
2. Hypothesis-driven weight-of-evidence analysis of endocrine disruption potential: a case study with triclosan.
Mihaich E; Capdevielle M; Urbach-Ross D; Slezak B
Crit Rev Toxicol; 2017 Apr; 47(4):263-285. PubMed ID: 28128023
[TBL] [Abstract][Full Text] [Related]
3. Hypothesis-driven weight of evidence analysis to determine potential endocrine activity of MTBE.
de Peyster A; Mihaich E
Regul Toxicol Pharmacol; 2014 Aug; 69(3):348-70. PubMed ID: 24813373
[TBL] [Abstract][Full Text] [Related]
4. Hypothesis-driven weight of evidence evaluation indicates styrene lacks endocrine disruption potential.
Borgert CJ
Crit Rev Toxicol; 2023 Feb; 53(2):53-68. PubMed ID: 37216681
[TBL] [Abstract][Full Text] [Related]
5. Hypothesis-driven weight of evidence framework for evaluating data within the US EPA's Endocrine Disruptor Screening Program.
Borgert CJ; Mihaich EM; Ortego LS; Bentley KS; Holmes CM; Levine SL; Becker RA
Regul Toxicol Pharmacol; 2011 Nov; 61(2):185-91. PubMed ID: 21803110
[TBL] [Abstract][Full Text] [Related]
6. A hypothesis-driven weight-of-evidence analysis to evaluate potential endocrine activity of perfluorohexanoic acid.
Borghoff SJ; Fitch S; Rager JE; Huggett D
Regul Toxicol Pharmacol; 2018 Nov; 99():168-181. PubMed ID: 30240830
[TBL] [Abstract][Full Text] [Related]
7. Review and analysis of the potential for glyphosate to interact with the estrogen, androgen and thyroid pathways.
Levine SL; Webb EG; Saltmiras DA
Pest Manag Sci; 2020 Sep; 76(9):2886-2906. PubMed ID: 32608552
[TBL] [Abstract][Full Text] [Related]
8. Weight-of-the-evidence evaluation of 2,4-D potential for interactions with the estrogen, androgen and thyroid pathways and steroidogenesis.
Neal BH; Bus J; Marty MS; Coady K; Williams A; Staveley J; Lamb JC
Crit Rev Toxicol; 2017 May; 47(5):345-401. PubMed ID: 28303741
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Tier I screening approaches for detecting endocrine-active compounds (EACs).
O'Connor JC; Cook JC; Marty MS; Davis LG; Kaplan AM; Carney EW
Crit Rev Toxicol; 2002; 32(6):521-49. PubMed ID: 12487364
[TBL] [Abstract][Full Text] [Related]
10. Relevance weighting of tier 1 endocrine screening endpoints by rank order.
Borgert CJ; Stuchal LD; Mihaich EM; Becker RA; Bentley KS; Brausch JM; Coady K; Geter DR; Gordon E; Guiney PD; Hess F; Holmes CM; LeBaron MJ; Levine S; Marty S; Mukhi S; Neal BH; Ortego LS; Saltmiras DA; Snajdr S; Staveley J; Tobia A
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):90-113. PubMed ID: 24510745
[TBL] [Abstract][Full Text] [Related]
11. Pronamide: Weight of evidence for potential estrogen, androgen or thyroid effects.
Marty MS; Papineni S; Coady KK; Rasoulpour RJ; Pottenger LH; Eisenbrandt DL
Regul Toxicol Pharmacol; 2015 Jul; 72(2):405-22. PubMed ID: 25846366
[TBL] [Abstract][Full Text] [Related]
12. The adrenal cortex and steroidogenesis as cellular and molecular targets for toxicity: critical omissions from regulatory endocrine disrupter screening strategies for human health?
Harvey PW; Everett DJ
J Appl Toxicol; 2003; 23(2):81-7. PubMed ID: 12666151
[TBL] [Abstract][Full Text] [Related]
13. Chlorpyrifos: weight of evidence evaluation of potential interaction with the estrogen, androgen, or thyroid pathways.
Juberg DR; Gehen SC; Coady KK; LeBaron MJ; Kramer VJ; Lu H; Marty MS
Regul Toxicol Pharmacol; 2013 Aug; 66(3):249-63. PubMed ID: 23524272
[TBL] [Abstract][Full Text] [Related]
14. A Comparison of ToxCast Test Results with In Vivo and Other In Vitro Endpoints for Neuro, Endocrine, and Developmental Toxicities: A Case Study Using Endosulfan and Methidathion.
Silva M; Pham N; Lewis C; Iyer S; Kwok E; Solomon G; Zeise L
Birth Defects Res B Dev Reprod Toxicol; 2015 Apr; 104(2):71-89. PubMed ID: 26017137
[TBL] [Abstract][Full Text] [Related]
15. Current limitations and recommendations to improve testing for the environmental assessment of endocrine active substances.
Coady KK; Biever RC; Denslow ND; Gross M; Guiney PD; Holbech H; Karouna-Renier NK; Katsiadaki I; Krueger H; Levine SL; Maack G; Williams M; Wolf JC; Ankley GT
Integr Environ Assess Manag; 2017 Mar; 13(2):302-316. PubMed ID: 27791330
[TBL] [Abstract][Full Text] [Related]
16. Application of Adverse Outcome Pathways to U.S. EPA's Endocrine Disruptor Screening Program.
Browne P; Noyes PD; Casey WM; Dix DJ
Environ Health Perspect; 2017 Sep; 125(9):096001. PubMed ID: 28934726
[TBL] [Abstract][Full Text] [Related]
17. A novel framework for interpretation of data from the fish short-term reproduction assay (FSTRA) for the detection of endocrine-disrupting chemicals.
Ankley GT; Jensen KM
Environ Toxicol Chem; 2014 Nov; 33(11):2529-40. PubMed ID: 25098918
[TBL] [Abstract][Full Text] [Related]
18. Endocrine disruptors and development of the reproductive system in the fetus and children: is there cause for concern?
Foster WG
Can J Public Health; 1998; 89 Suppl 1():S37-41, S52, S41-6. PubMed ID: 9654791
[TBL] [Abstract][Full Text] [Related]
19. Cross-species conservation of endocrine pathways: a critical analysis of tier 1 fish and rat screening assays with 12 model chemicals.
Ankley GT; Gray LE
Environ Toxicol Chem; 2013 Apr; 32(5):1084-7. PubMed ID: 23401061
[TBL] [Abstract][Full Text] [Related]
20. Sensitive detection of the endocrine effects of the estrogen analogue ethinylestradiol using a modified enhanced subacute rat study protocol (OECD Test Guideline no. 407).
Andrews P; Freyberger A; Hartmann E; Eiben R; Loof I; Schmidt U; Temerowski M; Folkerts A; Stahl B; Kayser M
Arch Toxicol; 2002 May; 76(4):194-202. PubMed ID: 12029382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
